December 16, 2025

Saturated Fat Benefits Vary by Risk

New systematic review finds cardiovascular benefits only in high-risk patients, challenges blanket dietary restrictions

Conexiant

December 12, 2025

Nine Breakthrough Studies Define 2025 Research

From GLP-1 cardioprotection to genome sequencing in newborns, this year's top research spans critical clinical frontiers.

Conexiant

December 04, 2025

BMI Changes Linked to Adult CHD

Swedish cohort shows weight normalization before young adulthood is associated with coronary disease risk comparable to peers with lifelong normal weight.

Conexiant

December 01, 2025

WHO Issues Conditional GLP-1 Obesity Guideline

New recommendations emphasize equity barriers, health-system readiness, and the need for integrated chronic-disease management.

Conexiant

March 06, 2025

Butter Raises, Plant Oils Lower Mortality

New 33-year study of 221,054 adults finds replacing butter with plant-based oils could reduce premature death risk by 17%, with olive, canola, and soybean oils showing strongest protective effects against cancer and cardiovascular mortality.

Conexiant

December 12, 2024

Brief, Vigorous Activity May Lower CV Risk in Women: Study Findings

A recent study shows that even 3.4 minutes of vigorous intermittent lifestyle physical activity per day could significantly reduce cardiovascular risk, particularly in non-exercising women.

Conexiant

December 10, 2024

Hormone Therapy Risks Vary: Tibolone Linked to Arterial Events

Recent study links tibolone use in menopausal hormone therapy to a 52% increased cardiovascular disease risk, emphasizing the need for tailored hormone therapy approaches and further research in BMJ.

Conexiant

November 14, 2024

AI-Powered Camera Detects Hypertension, Diabetes

An AI-powered high-speed video camera offers quick, no-contact screenings for high blood pressure and diabetes by analyzing blood flow features in face and palm skin, achieving impressive accuracies.

Reuters

November 19, 2024

Wide Variation in SGLT2i Use Across U.S. Hospitals

Study reveals hospital variation in SGLT2i prescriptions, with only 11 of 518 hospitals (2.1%) achieving ≥50% prescription rates while 232 hospitals (44.8%) prescribed to fewer than 10% of eligible heart failure patients, highlighting an implementation gap in evidence-based therapy.

Conexiant